drugset / Trial / NCT03300557

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

NCT03300557

Phase 2 Completed 40 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelPrevention

Summary

This pilot phase IIa trial studies how well exemestane works in treating patients with complex atypical hyperplasia of the endometrium/endometrial intraepithelial neoplasia or low grade endometrial cancer. Exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2017-11-15
Primary completion
2023-12-13
Completion
2025-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Exemestane Small molecule Oral